Home > Insider Trading > Filing (0001178913-22-004054)

Filing Details

Accession Number:: 0001178913-22-004054
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-11-15 16:13:24
Reporting Period:: 2022-11-11

Accepted Time:: 2022-11-15 16:13:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1638097	Entera Bio Ltd.	ENTX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1909822	Dana Yaacov-Garbeli	Kiryat Hadassah Minrav Building, 5Th Floor Jerusalem L3 9112002	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Par Value Nis 0.0000769 Per Share	Acquisiton	2022-11-11	30,000	$0.52	30,000	No	4	P	Indirect	By A2Z Counseling Ltd.
Ordinary Shares, Par Value Nis 0.0000769 Per Share	Acquisiton	2022-11-14	26,580	$0.54	56,580	No	4	P	Indirect	By A2Z Counseling Ltd.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By A2Z Counseling Ltd.
No	4	P	Indirect	By A2Z Counseling Ltd.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.